KalVista Pharmaceuticals公布了KONFIDENT在EKTERLY上研究遗传性血管性肿胀的数据，强调了对注射疗法的口服替代品的需求

Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked to injectable therapies

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), presented at the 20th German Allergy Congress in Düsseldorf, Germany from October 2–4, 2025. Across multiple ePoster presentations, EKTERLY demonstrated the ability to rapidly halt the progression of HAE attacks, deliver fast symptom relief and address key barriers associated with injectable therapies. Additional survey findings from German patients further highlight the urgent need for access to innovative on-demand HAE treatments across Europe.